References
- Hickey M, Davis S R, Sturdee D W. Treatment of menopausal symptoms: what shall we do now. Lancet 2005; 366: 409–421
- Bachmann G A. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005; 50: 155–165
- Bachmann G A. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999; 180: S312–S316
- Rolnick S J, Jackson J, Kopher R, Defor T A. Provider management of menopause after the findings of the Women's Health Initiative. Menopause 2007; 14: 441–449
- MacLennan A H, Broadbent J L, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev Oct, 2004; 18, CD002978
- National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms. Ann Intern Med 2005; 142: 1003–1013
- Skouby S O, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51: 8–14
- Pines A, Sturdee D W, Birkhäuser M H, et al. On behalf of the Board of the International Menopause Society. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
- Tan D, Darmasetiawan S, Haines C J, et al. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. Climacteric 2006; 9: 146–151
- North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168–182
- Ettinger B, Ensrud K E, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104: 443–451
- Johnson S R, Ettinger B, Macer J L, Ensrud K E, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005; 105: 779–787
- Bachmann G A, Schaefers M, Uddin A, Utian W H. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007; 110: 771–779
- Haines C J, Xing S M, Park K H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 264–276
- Meisels A. The maturation value. Acta Cytol 1967; 11: 249
- Tan D, Haines C J, Limpaphayom K K, Holinka C F, Ausmanas M K. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. Maturitas 2005; 52: 35–51
- Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–1079